Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest Celexa

Executive Summary

"If Forest terminates Warner-Lambert's co-promotion agreement because of [a Warner-Lambert] merger, under no circumstances would Forest be obligated to make payments until 2004," Forest Chairman Howard Solomon says in a Jan. 27 letter to "The Pink Sheet." Warner-Lambert told a Jan. 19 teleconference that "even if there is that change of control and they exercise their option, there's a period of step down payments that take place through the balance of the six year agreement" (1"The Pink Sheet" Jan. 24, p. 14). Forest and Warner-Lambert are in discussions to end the co-promotion agreement for the antidepressant

You may also be interested in...

Lipitor Holds Up In Merger Dispute; Warner-Lambert, Pfizer Beat Expectations

Warner-Lambert's Lipitor is showing no signs of a negative impact from the distractions caused by the hostile takeover bid launched by Warner's marketing partner Pfizer.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts